Option Care Health news

Zacks Rank #2 (Buy), strong Q2 2026 results with revenue and bottom-line uptick, solid operational execution, 7.8% earnings yield vs industry 4.7%, though modest 1.9% revenue growth and 8.7% earnings growth

The company delivered solid operational results with revenue growth of 1.9% YoY, improved profitability metrics (GAAP net income up 6.7%, diluted EPS up 12.9%), and raised full-year 2026 guidance. Strong operating cash flow of $184 million in Q2 and $150 million share repurchase demonstrate financial strength and management confidence in future performance.

The appointment of an experienced investor relations executive with a strong track record signals the company's commitment to enhancing investor engagement, transparency, and corporate visibility. This is a positive development for shareholder communication and demonstrates management's focus on executing growth strategy and creating long-term shareholder value.

Company missed Q1 2026 earnings consensus estimates, reduced full-year revenue guidance, experienced a 24% stock price decline, and is under investigation for potential securities law violations. Management's confident guidance statement in February proved inaccurate, raising concerns about disclosure practices.

Stock declined 26-30% following Q1 2026 revenue miss and substantial downward revision of FY2026 guidance ($125-225 million reduction). Management's recent reaffirmation of guidance two months prior raises concerns about potential misstatement of material facts regarding patient census and drug conversion assumptions.

Stock fell 30% following disappointing Q1 results and reduced full-year revenue guidance. The company's patient census assumptions proved significantly worse than expected, indicating operational challenges and potential prior misrepresentation of guidance.

Zacks Rank #2 (Buy) with strong Value Score of A, beat earnings consensus by 7.14% last quarter, and trades at attractive valuations (12.59X forward P/E and 11.51X P/CF). However, modest 0.5% monthly gain suggests slower momentum compared to DGX.

Infusion business continues as core growth engine with high-single-digit organic revenue growth outpacing industry growth. Company is expanding ambulatory infusion footprint and clinic visits are rising 20%+ YoY, with positive outlook for continued acute growth and long-term upside from Medicare coverage expansion.

Subject of securities investigation by Johnson Fistel on behalf of investors who suffered losses, indicating potential legal and financial issues.